




RealRate

PHARMACEUTICAL 2015

Acura Pharmaceuticals INC
Rank 213 of 274



The relative strengths and weaknesses of Acura Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acura Pharmaceuticals INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 0.64% points. The greatest weakness of Acura Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 113% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	13,231
Cost of Goods Sold	0
Intangible Assets	1,845
Liabilities, Current	2,992
Liabilities, Non-Current	0
Other Assets	162
Other Compr. Net Income	-32
Other Expenses	428
Other Liabilities	8,151
Other Net Income	-1,010
Other Revenues	751
Property and Equipment	957
Research and Development	4,582
Selling, General and Administrative Expense	7,940

Output Variable	Value in 1000 USD
Assets	16,195
Liabilities	11,143
Expenses	12,950
Revenues	751
Stockholders Equity	5,052
Net Income	-13,209
Comprehensive Net Income	-13,225
BaseVar	21,040
ECR before LimitedLiability	-16%
Economic Capital Ratio	141%